NCT03201835View on ClinicalTrials.gov

5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 24, 2015

Primary Completion Date

December 6, 2015

Study Completion Date

June 6, 2016

Conditions
Healthy Volunteers
Interventions
DRUG

PNL-THC:CBD soft gelatin capsule

3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)

DRUG

Sativex

spray X 4 actuations

DRUG

CBD hard capsule dose 1

1 hard capsule containing 10 mg CBD

DRUG

P-PNL-THC:CBD soft gelatin capsule

2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)

DRUG

CBD hard capsule dose 2

1 hard capsule containing 100 mg CBD

Trial Locations (1)

Unknown

Clinical Research Center (CRC)- Souraskey Medical center, Tel Aviv

Sponsors
All Listed Sponsors
lead

PhytoTech Therapeutics, Ltd.

INDUSTRY

NCT03201835 - 5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers | Biotech Hunter | Biotech Hunter